Absence of autophosphorylation site Y882 in the p185neu oncogene product correlates with a reduction of transforming potential
Hongtao Zhang(Chinese Academy of Sciences), Xiaolan Qian(National Cancer Institute), Huizhen Zhao(University of Pennsylvania), Donald M. O’Rourke(University of Pennsylvania), Yasunori Mikami(University of Pennsylvania), Ramachandran Murali(The Wistar Institute), Mark I. Greene(University of Pennsylvania), James G. Davis(National Cancer Institute)
Cited by 22
Related Papers
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
|The Lancet Oncology|2017|1.1k
National Survey of Drug-Resistant Tuberculosis in China
|New England Journal of Medicine|2012|649
ErbB receptors: from oncogenes to targeted cancer therapies
|Journal of Clinical Investigation|2007|578
Advances in clinical immunotherapy for gastric cancer
|Biochimica et Biophysica Acta (BBA) - Reviews on Cancer|2021|435
CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges
|Neuro-Oncology|2018|314